Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC). Bleeding during systemic anticoagulation wit...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Critical Care |
| Online Access: | http://dx.doi.org/10.1155/2016/7938062 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561075609927680 |
|---|---|
| author | Kenichi Nitta Hiroshi Imamura Akihiro Yashio Satoko Kashima Katsunori Mochizuki |
| author_facet | Kenichi Nitta Hiroshi Imamura Akihiro Yashio Satoko Kashima Katsunori Mochizuki |
| author_sort | Kenichi Nitta |
| collection | DOAJ |
| description | Introduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC). Bleeding during systemic anticoagulation with edoxaban presents a therapeutic conundrum, because there is currently no safe or efficacious reversal agent to stop major bleeding. Case Report. A 51-year-old woman had multiple traumatic injuries, including lower limb fractures. On day 8, she developed deep venous thrombosis, and edoxaban was administered orally. On day 38, she developed fungemia, which was treated with an antifungal drug. On day 43, she presented with dyspnea. Chest computed tomography scan showed bilateral diffuse ground-glass opacities in the whole lung fields. The results of the subsequent workup (i.e., serum levels of the antineutrophil cytoplasmic antibody, antinuclear antibody, and antiglomerular basement membrane antibody) and microbiological study were unremarkable. Based on these findings, her condition was diagnosed as diffuse alveolar hemorrhage (DAH) associated with edoxaban therapy. The lung opacities disappeared spontaneously after edoxaban therapy was discontinued. Conclusion. DAH is a dangerous complication associated with edoxaban therapy. DOACs, including edoxaban, should be prescribed with caution, especially for patients in a critical condition. |
| format | Article |
| id | doaj-art-18fdf782697345b8924e8b31eefbc682 |
| institution | Kabale University |
| issn | 2090-6420 2090-6439 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Critical Care |
| spelling | doaj-art-18fdf782697345b8924e8b31eefbc6822025-02-03T01:25:57ZengWileyCase Reports in Critical Care2090-64202090-64392016-01-01201610.1155/2016/79380627938062Diffuse Alveolar Hemorrhage Associated with Edoxaban TherapyKenichi Nitta0Hiroshi Imamura1Akihiro Yashio2Satoko Kashima3Katsunori Mochizuki4Department of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, JapanDepartment of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, JapanDepartment of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, JapanDepartment of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, JapanDepartment of Emergency and Critical Care Medicine, Shinshu University School of Medicine, Nagano, JapanIntroduction. The main adverse effect of anticoagulant therapy is bleeding, and major bleeding, including intracranial, gastrointestinal, and retroperitoneal bleeding, has been reported as an adverse effect of edoxaban, a direct oral anticoagulant (DOAC). Bleeding during systemic anticoagulation with edoxaban presents a therapeutic conundrum, because there is currently no safe or efficacious reversal agent to stop major bleeding. Case Report. A 51-year-old woman had multiple traumatic injuries, including lower limb fractures. On day 8, she developed deep venous thrombosis, and edoxaban was administered orally. On day 38, she developed fungemia, which was treated with an antifungal drug. On day 43, she presented with dyspnea. Chest computed tomography scan showed bilateral diffuse ground-glass opacities in the whole lung fields. The results of the subsequent workup (i.e., serum levels of the antineutrophil cytoplasmic antibody, antinuclear antibody, and antiglomerular basement membrane antibody) and microbiological study were unremarkable. Based on these findings, her condition was diagnosed as diffuse alveolar hemorrhage (DAH) associated with edoxaban therapy. The lung opacities disappeared spontaneously after edoxaban therapy was discontinued. Conclusion. DAH is a dangerous complication associated with edoxaban therapy. DOACs, including edoxaban, should be prescribed with caution, especially for patients in a critical condition.http://dx.doi.org/10.1155/2016/7938062 |
| spellingShingle | Kenichi Nitta Hiroshi Imamura Akihiro Yashio Satoko Kashima Katsunori Mochizuki Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy Case Reports in Critical Care |
| title | Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy |
| title_full | Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy |
| title_fullStr | Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy |
| title_full_unstemmed | Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy |
| title_short | Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy |
| title_sort | diffuse alveolar hemorrhage associated with edoxaban therapy |
| url | http://dx.doi.org/10.1155/2016/7938062 |
| work_keys_str_mv | AT kenichinitta diffusealveolarhemorrhageassociatedwithedoxabantherapy AT hiroshiimamura diffusealveolarhemorrhageassociatedwithedoxabantherapy AT akihiroyashio diffusealveolarhemorrhageassociatedwithedoxabantherapy AT satokokashima diffusealveolarhemorrhageassociatedwithedoxabantherapy AT katsunorimochizuki diffusealveolarhemorrhageassociatedwithedoxabantherapy |